Remarkable progress has been made in understanding and treating heart failure. Among other developments, angiotensin-converting enzyme inhibitors and b blockers have been found to have beneficial therapeutic effects, reinforcing the view that heart failure may be both a hemodynamic and a neurohumoral disorder. The Japanese Heart Failure Society was established to curb the threat of heart failure through research, education, and clinical practice. At the Societys 2nd Annual Scientific Meeting in Sapporo, molecular biologists, physiologists, clinicians, surgeons, and researchers in related…mehr
Remarkable progress has been made in understanding and treating heart failure. Among other developments, angiotensin-converting enzyme inhibitors and b blockers have been found to have beneficial therapeutic effects, reinforcing the view that heart failure may be both a hemodynamic and a neurohumoral disorder. The Japanese Heart Failure Society was established to curb the threat of heart failure through research, education, and clinical practice. At the Societys 2nd Annual Scientific Meeting in Sapporo, molecular biologists, physiologists, clinicians, surgeons, and researchers in related fields met to strengthen professional bonds for the ultimate goal of preventing death from heart failure. This book contains presentations from the Sapporo conference that provide new insights into heart failure in the areas of pathophysiology, cardiac sudden death, medical and surgical treatment, and promising new gene therapy.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
1 New Insights in the Pathophysiology of Heart Failure.- 1.1 Neurohormones in Advanced Heart Failure.- 1.2 Recent Progress in Natriuretic Hormone Research.- 1.3 Cytokines and Heart Failure: Pathophysiological Roles and Therapeutic Implications.- 1.4 Endothelium Dysfunction in Heart Failure: A Review.- 1.5 Pathogenesis of Myocardial Injury and Cell Death in Myocarditis: Its Relation to the Fas/Fas Ligand Pathway.- 1.6 Mechanisms of Acute Cardioprotection with Ischemic Preconditioning: Protein Kinase C and Beyond.- 1.7 Role of NO in Myocardial Injury Induced by Oxidative Stress: Ischemia, Myocarditis, Cardiomyopathy, and Heart Failure.- 1.8 Cardiac Remodeling: Role of Neovascularization in Heart Failure.- 2 Heart Failure and Cardiac Sudden Death.- 2.1 Long QT Syndrome as a Cause of Cardiac Sudden Death.- 2.2 ICD Therapy: Can It Prevent Sudden Death in CHF Patients?.- 2.3 Antiarrhythmic Drug Therapy for Sudden Cardiac Death in CHF Guided by the Sicilian Gambit.- 3 Medical Treatment of Heart Failure: Beyond ACE Inhibitors.- 3.1 Clinical Practice Guidelines in Heart Failure: State of the Art in the United States.- 3.2 Beyond ACE Inhibitors: Angiotensin II Antagonism in Heart Failure, An Emerging Role for Losartan.- 3.3 Beta-blockers in Heart Failure: Where Do We Stand Today?.- 3.4 Endothelin Antagonism in the Treatment of Heart Failure.- 3.5 Heart Failure: Potential Benefit of Growth Hormone Therapy.- 3.6 Role of Adenosine in Cardioprotection.- 4 Gene Therapy for Heart Failure: Current Status and Future Prospects.- 4.1 In Vivo Gene Supplementation for the Therapy of Cardiomyopathy.- 4.2 ?-Adrenergic Receptor Desensitization in Cardiac Disease: Insights from Gene-Targeted Mice.- 4.3 Gene Therapy for Myocardial Infarction: A Real Medicine in the Next Millenium?.- 4.4 FromScar Tissues to Viable Myocytes: A Novel Therapeutic Strategy for the Treatment of Heart Failure.- 5 Surgical Treatment for Heart Failure.- 5.1 Treatment of Profound Heart Failure by Ventricular Assist System.- 5.2 Left Ventriculoplasty for End-Stage Cardiomyopathy.
1 New Insights in the Pathophysiology of Heart Failure.- 1.1 Neurohormones in Advanced Heart Failure.- 1.2 Recent Progress in Natriuretic Hormone Research.- 1.3 Cytokines and Heart Failure: Pathophysiological Roles and Therapeutic Implications.- 1.4 Endothelium Dysfunction in Heart Failure: A Review.- 1.5 Pathogenesis of Myocardial Injury and Cell Death in Myocarditis: Its Relation to the Fas/Fas Ligand Pathway.- 1.6 Mechanisms of Acute Cardioprotection with Ischemic Preconditioning: Protein Kinase C and Beyond.- 1.7 Role of NO in Myocardial Injury Induced by Oxidative Stress: Ischemia, Myocarditis, Cardiomyopathy, and Heart Failure.- 1.8 Cardiac Remodeling: Role of Neovascularization in Heart Failure.- 2 Heart Failure and Cardiac Sudden Death.- 2.1 Long QT Syndrome as a Cause of Cardiac Sudden Death.- 2.2 ICD Therapy: Can It Prevent Sudden Death in CHF Patients?.- 2.3 Antiarrhythmic Drug Therapy for Sudden Cardiac Death in CHF Guided by the Sicilian Gambit.- 3 Medical Treatment of Heart Failure: Beyond ACE Inhibitors.- 3.1 Clinical Practice Guidelines in Heart Failure: State of the Art in the United States.- 3.2 Beyond ACE Inhibitors: Angiotensin II Antagonism in Heart Failure, An Emerging Role for Losartan.- 3.3 Beta-blockers in Heart Failure: Where Do We Stand Today?.- 3.4 Endothelin Antagonism in the Treatment of Heart Failure.- 3.5 Heart Failure: Potential Benefit of Growth Hormone Therapy.- 3.6 Role of Adenosine in Cardioprotection.- 4 Gene Therapy for Heart Failure: Current Status and Future Prospects.- 4.1 In Vivo Gene Supplementation for the Therapy of Cardiomyopathy.- 4.2 ?-Adrenergic Receptor Desensitization in Cardiac Disease: Insights from Gene-Targeted Mice.- 4.3 Gene Therapy for Myocardial Infarction: A Real Medicine in the Next Millenium?.- 4.4 FromScar Tissues to Viable Myocytes: A Novel Therapeutic Strategy for the Treatment of Heart Failure.- 5 Surgical Treatment for Heart Failure.- 5.1 Treatment of Profound Heart Failure by Ventricular Assist System.- 5.2 Left Ventriculoplasty for End-Stage Cardiomyopathy.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
